Overview

• The National Institute for Health and Care Excellence has issued a quality standard mandating structured behavioural and clinical support for up to one year after NHS patients stop GLP-1 injections such as Mounjaro and Wegovy
• Freedom of Information data show only eight of 42 Integrated Care Boards and four NHS systems currently provide GP prescribing of Mounjaro despite its June authorisation
• Around 240,000 people with the highest clinical need are earmarked for NHS treatment over three years, compared with an estimated 1.5 million private users who remain ineligible for aftercare
• The guidance highlights building long-term habits through self-monitoring tools, online communities, family-led interventions and local activity programmes
• Drug makers warn that slow and uneven rollout may prompt patients to seek potentially unsafe, unregulated sources for their weight-loss jabs